explore -WSS

explore

author：focus 2025-08-12 08:25:18 - browse：3

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Thermo Fisher plant for manufacturing gene therapies to expand

entertainment

WSS

Experts study whether long Covid risk adds up with each reinfection

Biogen joins immunology wave with $1.15 billion acquisition of HI

How AI helped researchers track recovery from depression

EpiPen alternative approval delay highlights citizen petition issue

FDA panel to weigh approval of NurOwn, controversial ALS drug

Thermo Fisher plant for manufacturing gene therapies to expand

explore

explore

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Fentanyl is making it harder to start addiction treatment

Peter Hotez and the public health issue of online harassment

Microbiome research is starting to find links to chronic diseases

Guidelines to prevent youth baseball injuries need more muscle

Readout LOUD podcast: possible new ALS drug, artificial wombs

Virginia high school admissions case could be legal follow

Scrutiny of post

Activists slam private health insurers over coverage restrictions

FDA panel to weigh approval of NurOwn, controversial ALS drug

focus

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Changes to biosimilar regulatory framework must prioritize patients

Senators: Long

CDC advisers recommend seasonal use of Pfizer RSV shot

Senators: Long

Scrutiny of post

knowledge

hotspot

entertainment

hotspot